Search website

If you cannot find, what you are looking for, try searching for it below or visit our FAQ-page.

Close
News & Events »
Tillotts partners Menarini to extend Asacol® to the People’s Republic of China

Press Release

Tillotts partners Menarini to extend Asacol® to the People’s Republic of China

RHEINFELDEN, Switzerland, October, 28th, 2019 – Tillotts Pharma AG (“Tillotts”), par[...] Read more »
Tillotts Pharma AG and LabGenius Enter Development Agreement in Inflammatory Bowel Diseases

Press Release

Tillotts Pharma AG and LabGenius Enter Development Agreement in Inflammatory Bowel Diseases

RHEINFELDEN, Switzerland, 14 March 2019 – Tillotts Pharma AG (“Tillotts”), part of t[...] Read more »
Tillotts Pharma AG announces launch of ASACOL<sup>TM</sup> 1600 mg (mesalazine)* for ulcerative colitis

Press Release

Tillotts Pharma AG announces launch of ASACOLTM 1600 mg (mesalazine)* for ulcerative colitis

RHEINFELDEN, Switzerland, 22 January 2019 – Tillotts Pharma AG (“Tillotts”), part of[...] Read more »
Innovation: Poster on OPTICORE<sup>TM</sup> Nominated for the 2018 AAPS Best Abstract Award

Press Release

Innovation: Poster on OPTICORETM Nominated for the 2018 AAPS Best Abstract Award

RHEINFELDEN, Switzerland, 22 October 2018 – Tillotts Pharma AG (“Tillotts”) is proud[...] Read more »
Tillotts Pharma AG and Zeria Group appoint Dr. Karima Boubekeur as new Global Head of Innovation

Press Release

Tillotts Pharma AG and Zeria Group appoint Dr. Karima Boubekeur as new Global Head of Innovation

RHEINFELDEN, Switzerland, September 3rd 2018 – Tillotts Pharma AG (“Tillotts”) an[...] Read more »
Tillotts Pharma AG signs POTELLIGENT<sup>®</sup> CHOK1SV<sup>TM</sup> Cell Line Technology Licensing Agreement with Lonza and BioWa

Press Release

Tillotts Pharma AG signs POTELLIGENT® CHOK1SVTM Cell Line Technology Licensing Agreement with Lonza and BioWa

• Tillotts Pharma AG will use the POTELLIGENT® CHOK1SV™ Cell Line, developed by Lonza[...] Read more »
1 2 3 5